- Monoclonal antibody generation using immunization in mice
- Hybridoma generation and selection
- cDNA sequence (DNA) coding for VH and VL and subsequently expressed on human IgG constant region
- Humanization possible through a partner (Panorama Research Inc., Sunnyville, CA; Antitope Ltd, UK) and testing of various humanized versions of the antibody leads in functional potency assays
Monoclonal Antibody Generation


Cell Line Development
- Cloning of DNA sequences in our CHOBC® vectors
- Stable transfection of the proprietary CHOBC®cells
- Selection of stable, high producing CHOBC® subclones
- Upscaling of lead clones and securing 50 L lock process
- Manufacturing of recombinant protein up to hundreds of grams
- All relevant analytics and assays for protein characterization
Upstream Process Development
- Stirred Tank Bioreactors ranging between 1 and 50 L scale
- Modulation of the process to optimize titer and productivity (routine titers of 2 – 6 g/L)
- Modulation of the process to target both the acidic and basic species dependent on the need
- Mannosylation, galactosylation and fucosylation can either be increased or decreased


Downstream Process Development
- Design of cost-effective and robust DSP processes capable of producing pharmaceutical-grade biotherapeutics
- Optimization of cell clarification by depth filtration and sterile-grade filtration
- Screening and optimization of various chromatography types
- Set-up of normal flow and tangential flow filtration steps
- Optimization of virus removal and inactivation steps, including in depth knowledge of viral validation studies
- Antibody purification expertise: biosimilar and novel antibodies
- Developing purification protocols for basically all protein-based therapeutics
- Design of Experiment (DoE) solutions for process optimization and characterization
- Extensive experience with disposable technology, including charged membrane filters
- Scale up and technology transfer expertise
Analytical Development
- Extensive experience in (e.g. mass spectrometry-based) analysis of complex proteins including Mabs
- Peptide mapping, including full sequencing (UPLC-MS/MS)
- Intact protein and semi-intact protein mass spectrometry (UPLC-MS/MS)
- N-terminal and C-terminal protein sequencing (UPLC-MS/MS)
- Deamidation, oxidation, pyro-glu (UPLC-MS/MS)
- Determination of disulfide bonds (heterogeneity) (UPLC-MS/MS)
- Released Glycans (UPLC-FLR-MS)
- Determination of charge variants by Cation (CEX) and Anion (AEX)
- Exchange Chromatography & by cIEF isoelectric focusing
- Determination of aggregates and fragments by Size Exclusion
- Chromatography (UPLC-SEC)
- CE-SDS capillary electrophoresis
- Determination of (CHO-based) Host Cell Proteins
- High throughput MAb sample purification and sample analysis
- Method qualification and validation
- Technology transfer


(Bio)assay Development
- Flow Cytometry
- ELISA
- Functional proprietary cell-based assays, including proprietary membrane FcγR- and FcRn-based binding assays
- ADCC (using a proprietary effector cell line) and CDC
- Cytokine release assays
- Potency assays
- Immunogenicity assays